Navigation Links
IFRS Information - First Half of 2007
Date:9/13/2007

rge of $1.8 million for share based compensation under IFRS 2, Share Based Payments, (2006: $1.5 million).

Research and development (R&D)

R&D expenditure increased from $150.0 million in the six months to June 30, 2006 to $277.1 million in the six months to June 30, 2007.

The increase in R&D expenditure during the six months to June 2007 primarily results from a non-cash charge of $100.0 million recognized on the effective settlement of Shire's pre-existing relationship with New River. This charge represents the write-off of capitalized up-front and milestone payments made by Shire prior to the acquisition of New River. This charge is presented within R&D as at the time of the New River acquisition VYVANSE, although approved by the FDA, had not yet received the final scheduling classification from the Drug Enforcement Agency ("DEA") and was therefore not available for commercial sale. Further details in respect of this charge are included in Note 3 to these IFRS interim financial statements.

Excluding this charge of $100 million on the effective settlement of the pre-existing relationship with New River, R&D expenditure in the six months to June 30, 2007 was $177.1 million, (2006: $150.0 million), an increase of $27.1 million, (18%). In 2007, R&D expenditure includes costs associated with Phase 3(b) and Phase 4 studies to support new product launches and the continuation of Phase 3 trials on GA-GCB, the development of the Women's Health and the New River franchises, pre-clinical development of three HGT projects, two new Phase 1 projects and two further pre-clinical projects.

For the six months to June 30, 2007 R&D expenditure included a charge of $5.4 million (2006: $2.8 million) in respect of share based compensation.

Selling, general and administrative (SG&A) expenses

SG&A expenses increased from $435.2 million in the six months to June 30, 2006 to $633.6 million in the six months to June 30, 2007, an increase of 46%. As
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Imaging and Analysis of DIGE Product Information Sheet, Rev B
2. Study affirms information technology-productivity link
3. TrafficCast integrates new information source
4. Rote education fails the Information Age
5. Weather information companies launch data product
6. TeraMedica launches information manager
7. Global information firm reaches diverse markets
8. Preparing for avian flu with information technology
9. Businesses cant hide personal information losses, theft
10. S.C. Johnson lands in No. 2 spot in Information Week 500 list
11. Crate and Barrel deploys Firstlogics Information Quality Suite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014 Research and Markets ... Biology Market 2014-2018" report to their offering. ... term synthetic biology covers the designing and engineering of ... as the redesigning of natural biological systems that provide ... a form of extreme genetic engineering because it not ...
(Date:7/28/2014)... NEW YORK , July 28, 2014 /PRNewswire/ ... for ConvergeHEALTH by Deloitte , has been ... Data Interchange Standards Consortium, a non-profit working to ... research data, particularly as it relates to electronic ... to continue CDISC,s mission of collaborating with organizations ...
(Date:7/28/2014)... July 28, 2014 Appistry, Inc. ... that bring the power of genomics to next-generation medicine, ... Appistry Pipeline Challenge . , Two Appistry staff ... the National Center for Genome Resources, and Mr. Neil ... Clinics of Kansas City. Rounding out the panel are ...
(Date:7/28/2014)...  InterMune, Inc. (NASDAQ: ITMN ) today ... financial results at the close of the U.S. markets ... webcast will be hosted by InterMune at 4:30 p.m. ... and others may participate in the conference call by ... replay of the webcast and teleconference will be available ...
Breaking Biology Technology:Global Synthetic Biology Market 2014-2018 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2InterMune to Release Second Quarter Financial Results on August 6 2
... 3, 2011 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ... March 31, 2011. The net income for the ... to a net loss of $14.1 million during the same ... March 31, 2011 was related primarily to the $34.2 million ...
... May 2, 2011 Anadys Pharmaceuticals, Inc. (Nasdaq: ... 2011 financial results on Thursday, May 5, 2011, after the ... conference call and webcast on Thursday, May 5, 2011 at ... 2011 financial results and highlights and to provide an update ...
... WAGENINGEN, Netherlands, May 2, 2011 Dyadic International, ... company focused on the discovery, development, manufacture and ... biopharmaceutical, biofuels and industrial enzyme industries, announced today ... B.V. ("Dyadic Netherlands"), has entered into a research ...
Cached Biology Technology:MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 2MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 3MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 4MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 5Anadys Pharmaceuticals to Report First Quarter 2011 Financial Results 2Dyadic Netherlands Enters Into R&D Collaboration With Sanofi Pasteur and EnGen Bio 2
(Date:7/29/2014)... news for parents of preterm babies latest research from ... time they become teenagers, the brains of many preterm children ... , A study conducted by the University,s Robinson Research ... child experiences no brain injury in early life, their cognitive ... their term-born peers. , However, the results of the study, ...
(Date:7/28/2014)... drugs already approved by the U.S. Food and Drug ... growth of certain bacterial pathogens inside human cells, including ... fever. The findings, published in mBio , the ... demonstrate a new way of identifying non-antibiotic drugs that ... A handful of drugs on the list inhibit the ...
(Date:7/28/2014)... TEMPE, Ariz. - Reactions among minerals and organic compounds ... deep carbon cycle, they provide energy for the deep ... life. However, very little is known about how minerals ... Arizona State University have demonstrated how a common mineral ... negating the need for toxic solvents or expensive ...
Breaking Biology News(10 mins):Preterm children's brains can catch up years later 2New route to identify drugs that can fight bacterial infections 2Mineral magic? Common mineral capable of making and breaking bonds 2Mineral magic? Common mineral capable of making and breaking bonds 3
... Springer will publish The HUGO Journal in cooperation ... Springer as Genomic Medicine, The HUGO Journal has ... Members of HUGO will receive free access to the ... discounted rates. The HUGO Journal will focus ...
... announced today that its Ewell Sale Stewart Library has ... Heritage Library. The BHL is a group of 12 ... worldwide dedicated to digitizing the published literature on biodiversity ... more widely available. Scanning and cataloguing the materials preserves ...
... New evidence for ice-free summers with intermittent winter sea ... a period of greenhouse conditions - gives a glimpse of ... warming. Records of past environmental change in the Arctic ... period between 100 and 65 million years ago leading up ...
Cached Biology News:Academy Library accepted to prestigious Biodiversity Heritage Library 2Arctic climate under greenhouse conditions in the Late Cretaceous 2Arctic climate under greenhouse conditions in the Late Cretaceous 3
... serum biomarker chip to profile the relative ... chip containing 120 human cancer serum biomarker-specific ... discovery scientists to study panels of biomarkers ... and the likelihood of recurrence of cancer. ...
... is a highly sensitive reagent for the ... a purified form of recombinant E. coli ... which is sensitive to changes in its ... Phosphate Sensor is rapid and tight (Kd ...
... fume hood ventilates and purifies ... release of exhaust. Bonded charcoal ... Configurations are available with vertical ... final HEPA filter, work bench ...
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation,of endotoxins for research purposes....
Biology Products: